Impact of Guideline-Directed Statin Intervention for Primary Prevention in Patients With Diabetes
Authors' conclusion
Significant gaps remain in GDSI use for high-risk patients with diabetes, conferring an increased risk of ASCVD outcomes and all-cause mortality.
Study context
- Population
- Patients without preexisting atherosclerotic cardiovascular disease (ASCVD) in a contemporary health care system, categorized by diabetes status and 10-year ASCVD risk: borderline (5–7.4%), intermediate (7.5–19.9%), high (≥20%)28,807 with diabetes
- Participants
- 282,298 patients
- Exposure
- No statin vs guideline-directed statin intensity (GDSI) in patients with diabetes
- Outcome
- Incident ASCVD and all-cause mortality
Methodological detailshealth care system-wide, Cox regression, fully adjusted models, stratified by 10-year ASCVD risk
- Health care system-wide
- Cox regression
- Fully adjusted models
- Stratified by 10-year ASCVD risk
Main finding
As reported in the abstract
All-cause mortality, patients with diabetes
No statin vs GDSIHazard ratio (95% CI)P value
Intermediate-risk
1.81(1.58–2.07)
P < 0.01for interactionHigh-risk
1.41(1.26–1.57)
P < 0.01for interactionObservational data: associations, not effects.
Further findings
GDSI use in intermediate- and high-risk patients with diabetes · 5-year follow-up
- Receiving GDSI therapy
- Only two-thirds
Diabetes prevalence
- Had diabetes
- 28,807 (10.2%)
- Did not have diabetes
- 253,491 (89.8%)
Original publication
Impact of Guideline-Directed Statin Intervention for Primary Prevention in Patients With Diabetes. Diabetes Care. Published 18 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →